Northern Trust’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.37M | Buy |
344,521
+313,965
| +1,028% | +$4.96M | ﹤0.01% | 2479 |
|
|
2026
Q1 | $456K | Sell |
30,556
-1,648
| -5% | -$25.8K | ﹤0.01% | 3648 |
|
|
2025
Q4 | $585K | Buy |
32,204
+13,629
| +73% | +$230K | ﹤0.01% | 3604 |
|
|
2025
Q3 | $236K | Sell |
18,575
-4,098
| -18% | -$35.2K | ﹤0.01% | 3924 |
|
|
2025
Q2 | $113K | Hold |
22,673
| – | – | ﹤0.01% | 4085 |
|
|
2025
Q1 | $182K | Hold |
22,673
| – | – | ﹤0.01% | 3973 |
|
|
2024
Q4 | $168K | Buy |
+22,673
| New | +$242K | ﹤0.01% | 4036 |
|
|
2023
Q4 | – | Sell |
-45
| Closed | -$1.31K | – | 4478 |
|
|
2023
Q3 | $1.31K | Hold |
45
| – | – | ﹤0.01% | 4458 |
|
|
2023
Q2 | $3.85K | Hold |
45
| – | – | ﹤0.01% | 4518 |
|
|
2023
Q1 | $19K | Hold |
45
| – | – | ﹤0.01% | 4458 |
|
|
2022
Q4 | $54.7K | Hold |
45
| – | – | ﹤0.01% | 4263 |
|
|
2022
Q3 | $36K | Buy |
45
+5
| +13% | +$5.42K | ﹤0.01% | 4411 |
|
|
2022
Q2 | $58K | Sell |
40
-146
| -78% | -$195K | ﹤0.01% | 4365 |
|
|
2022
Q1 | $388K | Buy |
186
+1
| +0.5% | +$2.51K | ﹤0.01% | 3840 |
|
|
2021
Q4 | $907K | Buy |
185
+5
| +3% | +$30K | ﹤0.01% | 3580 |
|
|
2021
Q3 | $1.13M | Sell |
180
-33
| -15% | -$267K | ﹤0.01% | 3512 |
|
|
2021
Q2 | $2.01M | Buy |
213
+26
| +14% | +$218K | ﹤0.01% | 3352 |
|
|
2021
Q1 | $1.62M | Buy |
187
+12
| +7% | +$113K | ﹤0.01% | 3360 |
|
|
2020
Q4 | $1.33M | Buy |
175
+11
| +7% | +$76.4K | ﹤0.01% | 3394 |
|
|
2020
Q3 | $1.07M | Buy |
164
+41
| +33% | +$308K | ﹤0.01% | 3368 |
|
|
2020
Q2 | $920K | Buy |
123
+25
| +26% | +$181K | ﹤0.01% | 3386 |
|
|
2020
Q1 | $703K | Buy |
98
+19
| +24% | +$201K | ﹤0.01% | 3352 |
|
|
2019
Q4 | $1.22M | Sell |
79
-2
| -2% | -$21.1K | ﹤0.01% | 3327 |
|
|
2019
Q3 | $769K | Buy |
81
+62
| +326% | +$692K | ﹤0.01% | 3459 |
|
|
2019
Q2 | $304K | Buy |
19
+6
| +46% | +$90.9K | ﹤0.01% | 3694 |
|
|
2019
Q1 | $222K | Buy |
13
+6
| +86% | +$89.8K | ﹤0.01% | 3752 |
|
|
2018
Q4 | $65K | Buy |
7
+2
| +40% | +$22.3K | ﹤0.01% | 4000 |
|
|
2018
Q3 | $63K | Hold |
5
| – | – | ﹤0.01% | 4105 |
|
|
2018
Q2 | $59K | Sell |
5
-6
| -55% | -$71.5K | ﹤0.01% | 4100 |
|
|
2018
Q1 | $135K | Buy |
11
+7
| +175% | +$78.9K | ﹤0.01% | 3902 |
|
|
2017
Q4 | $36K | Buy |
+4
| New | +$17.2K | ﹤0.01% | 4102 |
|
Other funds holding AVTX
Northern Trust's AVTX Position: Q2 2026 in Review
Northern Trust increased its Avalo Therapeutics (AVTX) stake by 1,028% in Q2 2026, buying an estimated $4.96M and bringing the position to 344,521 shares worth $6.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2479.
Northern Trust first reported a position in AVTX in Q4 2017 and has held it in 31 quarters since. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.
- Northern Trust held 344,521 shares of Avalo Therapeutics worth $6.37M as of Q2 2026.
- Northern Trust bought 313,965 Avalo Therapeutics shares in Q2 2026, an estimated $4.96M.
- Avalo Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2479 holding.
- Northern Trust first reported a position in Avalo Therapeutics in Q4 2017 and has held it in 31 quarters since.
- 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.